Clinical Efficacy of Ovasave® is Linked to Lytic Molecule Expression by Gertner-Dardenne, J, Belmonte, N, Foussat, A

Get full text

Regulatory T Cell Engineered with Chimeric Antigen Receptor (CAR-Treg) for Inflammatory and Autoimmune Diseases by Belmonte, N, Gertner-dardenne, J, Foussat, A

Get full text

Treg‐based immunotherapy of non‐infectious uveitis (NIU) by Asnagli, H., Jacquin, M., Belmonte, N., Gertner‐Dardenne, J., Hubert, M.F., Sales, A., Foussat, A.

Get full text

162 - Regulatory T Cell Engineered with Chimeric Antigen Receptor (CAR-Treg) for Inflammatory and Autoimmune Diseases by Belmonte, N., Gertner-dardenne, J., Foussat, A.

Get full text

176 - Clinical Efficacy of Ovasave® is Linked to Lytic Molecule Expression by Gertner-Dardenne, J., Belmonte, N., Foussat, A.

Get full text

OP02 IL23R-CAR-Tregs: creating a therapeutic breakthrough for Crohn’s Disease by Cui, Y, Boulakirba, S, David, M, Bouchareychas, L, Rouquier, S, Sajuthi, S, Ayrault, M, Navarin, C, Lafon, A, Lara, G, Menardi, A, Saviane, G, Dumont, C, Abel, T, Fenard, D, Lu, H, de la Rosa, M, Gertner-Dardenne, J

Get full text

BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia by Benyamine, Audrey, Le Roy, A., Mamessier, Emilie, Gertner-Dardenne, J., Castanier, C., Orlanducci, F., Pouyet, L, Goubard, A., Collette, Y., Vey, N., Scotet, Emmanuel, Castellano, R., Olive, D.

Get full text

Human V 9V 2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts by Gertner-Dardenne, J., Castellano, R., Mamessier, Emilie, Garbit, S., Kochbati, E., Etienne, A., Charbonnier, A., Collette, Y., Vey, N., Olive, D.

Get full text